Abstract: The present disclosure relates to compositions, nucleic acid constructs, methods and kits thereof for cell induction or reprogramming cells to the dendritic cell state or antigen presenting cell state, based, in part, on the surprisingly effect described herein of novel use and combinations of transcription factors that permit induction or reprogramming of differentiated or undifferentiated cells into dendritic cells or antigen presenting cells. Such compositions, nucleic acid constructs, methods and kits can be used for inducing dendritic cells in vitro, ex vivo, or in vivo, and these induced dendritic cells or antigen presenting cells can be used for immunotherapy applications.
Type:
Grant
Filed:
April 5, 2018
Date of Patent:
May 31, 2022
Assignee:
Asgard Therapeutics AB
Inventors:
Carlos Filipe Ribeiro Lemos Pereira, Cristiana Ferreira Pires, Fabio Alexandre Fiuza Rosa